Table 3:
Prospective clinical trials for KTR treated with ICI.
| Study | Nivolumab in transplant patients | Tacrolimus and ICI | CONTRAC-1 |
|---|---|---|---|
| Cancer type | Any cancers (incurable, metastatic solid tumors) | Skin cancers (melanoma, cSCC, BCC, Merkel cell carcinoma) | cSCC |
| Transplant | Kidney | Kidney | Kidney |
| ICI | Nivolumab* | Nivolumab ± Ipilimumab | Cemiplimab |
| Immunosuppression | Keep the same dose | Tac (2–5 ng/ml), pred 5 mg/day | mTORi + dynamic pred |
| Patient # | 17 | 8 | 12 |
| Rejection | 2 (11.7%) | 2 (25%) | 0 (0%) |
| ORR (CR + PR) | 53% | 33% | 45% |
| Registry | ANZCTR CA209-993ISR | NCT03816332 | NCT03565783 |
| Primary institution | Royal Adelaide Hospital, multicenter | Johns Hopkins Hospital, multicenter | Dana Farber Cancer Institute |
| Australia | USA | USA | |
| Reference | Lancet Oncol (2022) | J Clin Oncol (2024) | J Clin Oncol (2024) |
cSCC: cutaneous squamous carcinoma, BCC: basal cell carcinoma, ORR: objective response rate, CR: complete response, PR: partial response, mTORi: mammalian target of rapamycin